Short answer
Anika Therapeutics, Inc. (ANIK) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
Anika Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results
- Disclosure furnished under Item 2.02, generally outside Section 18 liability
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $32.6M, up 16%, with Commercial Channel revenue up 17% to record $13.9M
- Gross margin expanded to 65%, driving $3.3M GAAP net income and $7.1M adjusted EBITDA
- Full-year 2026 guidance raised: revenue growth 5%-10%, adjusted EBITDA margin 13%-17%
- Cash fell to $38.4M from $57.5M at December 31, 2025, including $9.5M of share repurchases and $5.5M operating cash use
- 2027 Commercial Channel growth outlook reduced to 5%-15% from 10%-20%, excluding unapproved Hyalofast revenue due to FDA timing uncertainty
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Anika Therapeutics, Inc. 8-K filings
Get the next ANIK 8-K as it lands
Follow ANIK for push alerts, or ask the research agent what this filing means.